Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity DOI

Zilun Shi,

Lili Zhou, Xiaochun Wang

et al.

Archives of Microbiology, Journal Year: 2024, Volume and Issue: 206(8)

Published: July 16, 2024

Language: Английский

Tuberculosis vaccines and therapeutic drug: challenges and future directions DOI Creative Commons

Yajing An,

Ruizi Ni,

Zhuang Li

et al.

Molecular Biomedicine, Journal Year: 2025, Volume and Issue: 6(1)

Published: Jan. 22, 2025

Abstract Tuberculosis (TB) remains a prominent global health challenge, with the World Health Organization documenting over 1 million annual fatalities. Despite deployment of Bacille Calmette-Guérin (BCG) vaccine and available therapeutic agents, escalation drug-resistant Mycobacterium tuberculosis strains underscores pressing need for more efficacious vaccines treatments. This review meticulously maps out contemporary landscape TB development, focus on antigen identification, clinical trial progress, obstacles future trajectories in research. We spotlight innovative approaches, such as multi-antigen mRNA technology platforms. Furthermore, delves into current therapeutics, particularly multidrug-resistant (MDR-TB), exploring promising agents like bedaquiline (BDQ) delamanid (DLM), well potential host-directed therapies. The hurdles development encompass overcoming diversity, enhancing effectiveness across diverse populations, advancing novel Future initiatives emphasize combinatorial strategies, anti-TB compounds targeting pathways, personalized medicine treatment prevention. notable advances, persistent challenges diagnostic failures protracted regimens continue to impede progress. work aims steer research endeavors toward groundbreaking providing crucial insights prevention strategies.

Language: Английский

Citations

3
Synthesis of an Adjuvant-Free Single Polypeptide-Based Tuberculosis Subunit Vaccine that Elicits In Vivo Immunogenicity in Rats DOI

Supriya Phogat,

Jyoti Yadav,

Darshna Chaudhary

et al.

Molecular Biotechnology, Journal Year: 2025, Volume and Issue: unknown

Published: April 2, 2025

Language: Английский

Citations

1
Antigen Processing Pathways in Mycobacterium tuberculosis Pathogenesis and Links to Clinical Presentation DOI

Karolina D. Witt

IntechOpen eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: April 14, 2025

Mycobacterium tuberculosis (Mtb) is an intracellular pathogen that has co-evolved with humans and developed various decoy strategies to survive in hostile environments by manipulating host immunity its advantage. This occurs through selective antigen presentation at the cellular level, induction of dysfunctional immune responses, a clinical latency period hampers active surveillance disease transmission. The spectrum symptoms function responses may, but does not necessarily, correlate directly burden. chapter will explore biology tuberculosis, focusing on selected genes their products are crucial host-pathogen interactions, which subsequently result (TB). It look bacilli’s location, antigens’ release presentation, processing pathways, granuloma formation. Both pulmonary extrapulmonary presentations presented, including destructive role inflammation disease. also briefly mention Mtb used rapid diagnostics TB antigens design new vaccines.

Language: Английский

Citations

0
Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity DOI

Zilun Shi,

Lili Zhou, Xiaochun Wang

et al.

Archives of Microbiology, Journal Year: 2024, Volume and Issue: 206(8)

Published: July 16, 2024

Language: Английский

Citations

0